Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1134018

	registered interest
	date	24/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accelerated Access Collaborative
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will list the (a) criteria and (b) timelines for products to be considered in (i) the current round and (ii) future review rounds of the Accelerated Access Collaborative route.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	268506
	answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.</p><p>The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.</p><p>The AAC will consider the following areas of interest when determining which products to support:</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/07/2019 16:12:14 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1134019

	registered interest
	date	24/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accelerated Access Collaborative
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how products selected by the Accelerated Access Collaborative will be funded.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	268507
	answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>As announced in the Life Sciences Sector Deal 2, up to £2 million of Pathway Transformation Funding has been made available to support the use and integration of product selected by the Accelerated Access Collaborative (AAC) into every day practice within the National Health Service. In addition, four of the seven technology areas currently receiving AAC support have been selected to be funded by NHS England through the Innovation and Technology Payment programme (ITP). The ITP aims to remove financial and procurement barriers to support the NHS to adopt innovative medical devices, diagnostics, and digital products.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/07/2019 16:07:33 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1134020

	registered interest
	date	24/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accelerated Access Collaborative
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether all products considered by the Accelerated Access Collaborative will have to be cost-neutral to the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	268508
	answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>As it continues to drive forward the assessment and uptake of the best products for support, the Accelerated Access Collaborative (AAC) has been empowered to be flexible and pragmatic enough to identify truly game-changing innovations, that may not be cost-neutral in year, but are assessed by the National Institute for Health and Care Excellence to be both clinically and cost-effective. This will allow the AAC to identify products, or classes of products, that are most likely to significantly transform care in the National Health Service.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/07/2019 16:06:04 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1134021

	registered interest
	date	24/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accelerated Access Collaborative
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Accelerated Access Collaborative has to prioritise products which help control hospital-acquired infections.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	268509
	answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>The Accelerated Access Collaborative (AAC) is interested in identifying and supporting strategically important products that will have the biggest impact on patient health outcomes and/or the delivery of NHS services. This may include those which help control hospital-acquired infections.</p><p>The AAC has already had made significant progress towards getting the best innovations to patients quicker and at a better cost for the National Health Service.</p><p>Since 2018, NHS England has been supporting SecurAcath and Plus Sutures, products designed to reduce infection rates, on the Innovation and Technology Payment programme. SecurAcath is a device to secure catheters that reduces the infection risk for patients with a peripherally inserted central catheter and has benefited over 80,000 patients. Seven trusts with higher than 4% surgical site infection rates have adopted Plus Sutures, a triclosan coated suture, with more trusts to be supported this year.</p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/07/2019 16:12:48 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1134022

	registered interest
	date	24/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accelerated Access Collaborative
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how the Accelerated Access Collaborative plans to balance its focus on (a) medicines, (b) diagnostic tools and (c) digital services.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	268510
	answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>There are no restrictions on the type of innovation that can be supported by the Accelerated Access Collaborative (AAC). Medicinal products, therapeutic technologies, devices, diagnostics, and digital technologies are eligible to receive support.</p><p>In October 2018, the AAC announced it was supporting to increased uptake and use of 12 high performing products, which span seven technology areas, in the National Health Service. Of the seven categories selected for support, two are medicines, four are diagnostic tests, and one is a device.</p><p>Further information about the products the AAC are supporting can be found at the following link:</p><p><a href="https://www.nice.org.uk/aac" target="_blank">https://www.nice.org.uk/aac</a></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/07/2019 16:06:55 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1137416

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accelerated Access Collaborative
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will list (a) the criteria and (b) the timelines for products to be considered in (i) the current and (ii) future review rounds of the Accelerated Access Collaborative.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	274540
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.</p><p>The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.</p><p>The AAC will consider the following areas of interest when determining which products to support:</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p> </p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/07/2019 15:23:36 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1137418

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accelerated Access Collaborative
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what criteria the Accelerated Access Collaborative uses in relation to decision-making on (a) medicines, (b) diagnostic tools and (c) digital services.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	274542
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Accelerated Access Collaborative (AAC) is interested in supporting the most strategically important products that will have the biggest impact on patient health outcomes and delivery of National Health Service services.</p><p>When selecting products, the AAC will consider the following irrespective of innovation type (i.e. medicines, diagnostic tools, and digital products):</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p>Further information is available at the following link:</p><p><a href="https://www.nice.org.uk/aac" target="_blank">https://www.nice.org.uk/aac</a></p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/07/2019 15:33:03 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1144596

	registered interest
	date	04/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Alzheimer's Disease: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to improve the early detection of Alzheimer's disease.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	286747
	answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>Alzheimer's disease is the most common type of dementia in the United Kingdom.</p><p>The Challenge on Dementia 2020 sets out the ambition for two thirds of people with dementia to receive a formal diagnosis. This has been achieved and exceeded nationally. Our focus now is on reducing the variation in local diagnosis rates and NHS England have published guidance and put programmes in place to further improve the quality and timeliness of diagnosis across the country.</p><p>For example, the ‘Implementation guide and resource pack for dementia care’ published in July 2017 sets out key recommendations on how services should be configured to provide good quality diagnosis and post-diagnostic care for people with dementia and their carers. It includes key roles and activity in primary care and memory assessment services to facilitate an accurate and timely diagnosis of dementia, while ensuring access to appropriate support following diagnosis. The resource pack is available at the following link:</p><p><a href="https://www.england.nhs.uk/mental-health/dementia/implementation-guide-and-resource-pack-for-dementia-care/" target="_blank">https://www.england.nhs.uk/mental-health/dementia/implementation-guide-and-resource-pack-for-dementia-care/</a></p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 09/09/2019 16:15:34 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1132910

	registered interest
	date	18/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dementia: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the accuracy of dementia diagnoses.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	266210
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The Challenge on Dementia 2020 sets out the ambition for two thirds of people with dementia to receive a formal diagnosis. This has been achieved and exceeded nationally. Our focus now is on reducing the variation in local diagnosis rates and NHS England has published guidance and put programmes in place to further improve the quality and timeliness of diagnosis across the country.</p><p>For example, the ‘Implementation guide and resource pack for dementia care’ published in July 2017 sets out key recommendations on how services should be configured to provide good-quality diagnosis and post-diagnostic care for people with dementia and their carers. It includes key roles and activity in primary care and memory assessment services to facilitate an accurate and timely diagnosis of dementia, while ensuring access to appropriate support following diagnosis. The resource pack is available at the following link:</p><p><a href="https://www.england.nhs.uk/mental-health/dementia/implementation-guide-and-resource-pack-for-dementia-care/" target="_blank">https://www.england.nhs.uk/mental-health/dementia/implementation-guide-and-resource-pack-for-dementia-care/</a></p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/06/2019 14:40:04 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1129344

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dietetics: Recruitment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to increase the numbers of dietitians in the NHS and social care to support the NHS Long Term Plan priorities of tackling frailty in old age, obesity and type 2 diabetes and improving health outcomes within stroke, cancer and dementia care.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	259223
	answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>The National Health Service published its interim People Plan on 3 June. It sets out a plan of action to meet the health requirements of the population outlined in the NHS Long Term Plan. The interim People Plan puts NHS people at the heart of NHS policy. The development of the dietetic workforce was central to the allied health professionals workforce programme for the plan and was developed by engaging widely with staff, patients, employers, professional organisations, regulatory bodies, voluntary sector, academia and other experts. We expect the final People Plan to be published within two months of the Spending Review.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 11/06/2019 14:53:21 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon